InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical drug development company focused on proprietary small-molecule candidates for diseases with high unmet medical need. Through its BayMedica subsidiary, it also manufactures and sells bulk rare, non-intoxicating cannabinoids as ingredients for health and wellness applications.

34,5 %

−165,1 %

+7,5 %

6.99

6.47

— InMed Pharmaceuticals Inc.
%
Pharmaceutical drug candidates0% Early-stage proprietary compounds being developed for ocular, dermatology and neurodegenerative indications.
Cannabinoid ingredients100% Bulk rare cannabinoids manufactured and sold to B2B customers for health and wellness uses.
Contracted R&D and development0% Research, formulation, CMC and clinical development work supporting pipeline advancement.
Manufacturing services and processes0% Proprietary and conventional manufacturing approaches used to produce high-purity cannabinoid products.

InMed’s commercial customers are B2B buyers of rare cannabinoid raw materials, likely including ingredient formulators...

  • B2B cannabinoid ingredient buyersprimary

    Buy bulk rare, non-intoxicating cannabinoids for use as raw materials in health and wellness products.

  • Pharmaceutical licensing partnerssecondary

    May license or co-develop INM-755 and other pipeline assets to reduce development risk and fund advancement.

  • Clinical and research ecosystemsecondary

    CROs, CDMOs, investigators and consultants supporting preclinical and clinical development work.

  • Future prescription patientsemerging

    Patients with dry AMD, epidermolysis bullosa, itch-related skin conditions and Alzheimer’s disease.

InMed is headquartered in Vancouver, British Columbia, and is listed on Nasdaq in the United States...

  • •Headquartered in Vancouver, British Columbia, Canada
  • •Listed on Nasdaq Capital Market in the United States
  • •Commercial cannabinoid sales are exposed to cross-border trade rules
  • •U.S. and Canadian healthcare regulation shapes drug development
  • •Manufacturing approach supports flexible sourcing and production

InMed is prioritizing advancement of its proprietary pipeline while keeping BayMedica’s cannabinoid ingredient business...

01
Advance pipeline assets toward clinical and regulatory milestonesmedium-term

Clinical progress is the main path to value creation for a company with no approved products.

02
Monetize BayMedica’s cannabinoid ingredient businessshort-term

Commercial sales provide the only recurring revenue source while the pharma pipeline remains pre-revenue.

03
Pursue strategic partnershipsmedium-term

Partnering can reduce capital intensity and improve the odds of advancing assets like INM-755.

InMed is highly exposed to clinical, regulatory and financing risk because its drug candidates are early-stage and...

high

Clinical development failure

Product candidates are early stage and may not demonstrate safety or efficacy in trials.

Scope
INM-089, INM-755, INM-901
Materiality
high
high

Regulatory approval delay or denial

Drug candidates require lengthy and unpredictable FDA/Health Canada review processes.

Scope
All pipeline programs
Materiality
high
high

Cannabinoid market and policy change

BayMedica’s commercial inventory and sales depend on the legal treatment of non-intoxicating cannabinoids.

Scope
BayMedica commercial business
Materiality
high
high

Financing and going-concern pressure

The company has recurring operating losses and relies on external capital to fund operations.

Scope
Corporate liquidity
Materiality
high
medium

Nasdaq minimum bid price or listing compliance

Delisting risk can reduce liquidity and access to capital for a small-cap development company.

Scope
Common shares on Nasdaq Capital Market
Materiality
high
Revenue recognition timing
BayMedica sales and gross margin
Going-concern assessment
Liquidity disclosure and investor perception
Inventory valuation
Cost of sales and asset values
Share-based compensation and warrant valuation
Reported net loss and equity
R&D accrual estimates
Research and development expense

INSMED Inc

INSM · Pharmaceutical Preparations

LEXICON PHARMACEUTICALS, INC.

LXRX · Pharmaceutical Preparations

INSULET CORP

PODD · Surgical & Medical Instruments & Apparatus

Modular Medical, Inc.

MODD · Surgical & Medical Instruments & Apparatus

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

INOVIO PHARMACEUTICALS, INC.

INO · Pharmaceutical Preparations

: 28.4.2026